Cargando…

Uptake and cost of biosimilar filgrastim among Medicare and Medicaid populations in 2015-2018

BACKGROUND: The first biosimilar product filgrastim-sndz was approved by the FDA in 2015, but real-world evaluations of its uptake and cost in nationally representative populations are limited. OBJECTIVE: To evaluate the uptake and cost of filgrastim-sndz, relative to its originator filgrastim and a...

Descripción completa

Detalles Bibliográficos
Autor principal: Qian, Jingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391058/
https://www.ncbi.nlm.nih.gov/pubmed/33908273
http://dx.doi.org/10.18553/jmcp.2021.27.5.660